Journal: Frontiers in Immunology

Article Title: Persistent innate immune dysfunction and ZIKV replication in the gastrointestinal tract during SIV infection in pigtail macaques

doi: 10.3389/fimmu.2025.1535807

Figure Lengend Snippet: PBMC from SIV-infected PTM are less permissive to in vitro ZIKV infection. (A, B) Peripheral blood mononuclear cells (PBMC) were isolated from pigtail macaques prior to and at 2 and 6 weeks post-SIV infection and infected in vitro with ZIKV Brazil at a multiplicity of infection (MOI) of 2. Cells and supernatant were harvested 4, 24, and 48 hours post-infection. (A) Quantitative real-time PCR (qRT-PCR) for ZIKV RNA in PBMC. (B) Plaque assay for infectious Zika virus. (A, B) Medians with interquartile ranges are shown. Kruskal-Wallis test versus pre-SIV levels, p-values * ≤ 0.05. (C) Frequency of CD16+CD14+ monocytes and macrophages (Mon&Mac) (top panel) and dendritic cells (lower panel) in blood from uninfected and SIV-infected pigtail macaques. Wilcoxon matched-pairs signed rank test, p-values ≤ 0.05 considered significant. (D) Gene expression of PBMC in blood at Week 2 post-SIV (top panel) and Week 6 post-SIV (bottom panel). t-test between each timepoint relative to pre-SIV, p-values *<0.01 shown by orange dots.

Article Snippet: Plasma and/or CSF quantification by ELISA of human soluble CD14 (sCD14), human fatty acid binding protein 2 (FABP2) (Fisher Scientific, Waltham, MA) or human LPS binding protein (LBP) (Biometec, Germany) was performed per the manufacturer’s instruction.

Techniques: Infection, In Vitro, Isolation, Real-time Polymerase Chain Reaction, Quantitative RT-PCR, Plaque Assay, Virus, Gene Expression

Journal: Frontiers in Immunology

Article Title: Persistent innate immune dysfunction and ZIKV replication in the gastrointestinal tract during SIV infection in pigtail macaques

doi: 10.3389/fimmu.2025.1535807

Figure Lengend Snippet: Post-ZIKV recruitment of CD16+ monocytes and macrophages is dampened in the periphery, but enhanced in tissues in SIV-infected macaques. (A) Frequency of CD16+CD14+ monocytes and macrophages (Mon&Mac) in blood (left panel), rectum (center panel), and peripheral lymph node (right panel) after ZIKV infection. (B) Frequency of neutrophils in blood after ZIKV infection. (C) Concentration of myeloperoxidase (MPO) in plasma as measured by ELISA. (A-C) Medians with interquartile ranges are shown. Mann-Whitney test between groups, p-values * ≤ 0.05.

Article Snippet: Plasma and/or CSF quantification by ELISA of human soluble CD14 (sCD14), human fatty acid binding protein 2 (FABP2) (Fisher Scientific, Waltham, MA) or human LPS binding protein (LBP) (Biometec, Germany) was performed per the manufacturer’s instruction.

Techniques: Infection, Concentration Assay, Clinical Proteomics, Enzyme-linked Immunosorbent Assay, MANN-WHITNEY

Journal: Journal of Antimicrobial Chemotherapy

Article Title: No accelerated progression of subclinical atherosclerosis with integrase strand transfer inhibitors compared to non-nucleoside reverse transcriptase inhibitors

doi: 10.1093/jac/dkae383

Figure Lengend Snippet: Characteristics of patients according to the antiretroviral regimen composition

Article Snippet: D-dimer [Human D2D (D-Dimer) ELISA Kit], soluble ICAM-1 (sICAM-1) [Human ICAM-1/CD54 (intercellular adhesion molecule 1) ELISA Kit], soluble CD14 (sCD14) [Human sCD14 (Soluble Cluster of Differentiation 14) ELISA Kit] and soluble CD163 (sCD163) [Human sCD163 (Soluble Cluster of Differentiation 163) ELISA Kit] were measured by enzyme-linked immunosorbent assay (ELISA Kits, Elabscience Biotechnology Inc., USA) with an automated instrument (Dynex DS2 ® ELISA system).

Techniques: Cell Counting

Journal: Journal of Antimicrobial Chemotherapy

Article Title: No accelerated progression of subclinical atherosclerosis with integrase strand transfer inhibitors compared to non-nucleoside reverse transcriptase inhibitors

doi: 10.1093/jac/dkae383

Figure Lengend Snippet: Characteristics of patients according to the progression of cIMT during the 2 year follow-up

Article Snippet: D-dimer [Human D2D (D-Dimer) ELISA Kit], soluble ICAM-1 (sICAM-1) [Human ICAM-1/CD54 (intercellular adhesion molecule 1) ELISA Kit], soluble CD14 (sCD14) [Human sCD14 (Soluble Cluster of Differentiation 14) ELISA Kit] and soluble CD163 (sCD163) [Human sCD163 (Soluble Cluster of Differentiation 163) ELISA Kit] were measured by enzyme-linked immunosorbent assay (ELISA Kits, Elabscience Biotechnology Inc., USA) with an automated instrument (Dynex DS2 ® ELISA system).

Techniques: Cell Counting

Journal: Journal of Antimicrobial Chemotherapy

Article Title: No accelerated progression of subclinical atherosclerosis with integrase strand transfer inhibitors compared to non-nucleoside reverse transcriptase inhibitors

doi: 10.1093/jac/dkae383

Figure Lengend Snippet: Univariate and multivariate analysis of factors associated with cIMT increase analysed as a continuous variable during the 2 year follow-up

Article Snippet: D-dimer [Human D2D (D-Dimer) ELISA Kit], soluble ICAM-1 (sICAM-1) [Human ICAM-1/CD54 (intercellular adhesion molecule 1) ELISA Kit], soluble CD14 (sCD14) [Human sCD14 (Soluble Cluster of Differentiation 14) ELISA Kit] and soluble CD163 (sCD163) [Human sCD163 (Soluble Cluster of Differentiation 163) ELISA Kit] were measured by enzyme-linked immunosorbent assay (ELISA Kits, Elabscience Biotechnology Inc., USA) with an automated instrument (Dynex DS2 ® ELISA system).

Techniques: Cell Counting

Journal: Journal of Antimicrobial Chemotherapy

Article Title: No accelerated progression of subclinical atherosclerosis with integrase strand transfer inhibitors compared to non-nucleoside reverse transcriptase inhibitors

doi: 10.1093/jac/dkae383

Figure Lengend Snippet: Patients’ characteristics according to the antiretroviral regimen composition after propensity score matching

Article Snippet: D-dimer [Human D2D (D-Dimer) ELISA Kit], soluble ICAM-1 (sICAM-1) [Human ICAM-1/CD54 (intercellular adhesion molecule 1) ELISA Kit], soluble CD14 (sCD14) [Human sCD14 (Soluble Cluster of Differentiation 14) ELISA Kit] and soluble CD163 (sCD163) [Human sCD163 (Soluble Cluster of Differentiation 163) ELISA Kit] were measured by enzyme-linked immunosorbent assay (ELISA Kits, Elabscience Biotechnology Inc., USA) with an automated instrument (Dynex DS2 ® ELISA system).

Techniques: Cell Counting

Journal: Microbiology Spectrum

Article Title: SARS-CoV-2 infection is associated with intestinal permeability, systemic inflammation, and microbial dysbiosis in hospitalized patients

doi: 10.1128/spectrum.00680-24

Figure Lengend Snippet: Plasma biomarker concentrations in all enrolled patients ^a

Article Snippet: Gut barrier damage biomarkers, including LBP (cell sciences CKH113), sCD14 (R&D Systems QK383), zonulin (MyBioSource MBS706368), and I-FABP (R&D Systems DFBP20), were measured using commercially available assays according to the manufacturer’s guidelines.

Techniques: Biomarker Assay

Journal: Microbiology Spectrum

Article Title: SARS-CoV-2 infection is associated with intestinal permeability, systemic inflammation, and microbial dysbiosis in hospitalized patients

doi: 10.1128/spectrum.00680-24

Figure Lengend Snippet: Plasma concentrations of gut barrier damage markers and circulating fatty acids in COVID-19 patients and healthy controls. Plasma concentrations for I-FABP ( A ), zonulin ( B ), LBP ( C ), and sCD14 ( D ) measured by enzyme-linked immunosorbent assay (ELISA) and circulating fatty acids propionic acid ( E ), decanoic acid ( F ), butyric acid ( G ), nonanoic acid ( H ), and isovaleric acid ( I ) measured by liquid chromotagraphy-tandem mass spectrometry ( LC-MS/MS). Comparisons between groups were performed by Kruskal–Wallis tests for all analytes, but only followed by Dunn post hoc tests if adjusted P -values were below 0.05; thus, all plots showing pairwise comparisons had significant Kruskal–Wallis tests. Pairwise Dunn tests within each variable were also FDR-adjusted using the Benjamini–Hochberg method . P -values <0.05 were considered significant.

Article Snippet: Gut barrier damage biomarkers, including LBP (cell sciences CKH113), sCD14 (R&D Systems QK383), zonulin (MyBioSource MBS706368), and I-FABP (R&D Systems DFBP20), were measured using commercially available assays according to the manufacturer’s guidelines.

Techniques: Enzyme-linked Immunosorbent Assay, Mass Spectrometry, Liquid Chromatography with Mass Spectroscopy